Technical Analysis for PLX - Protalix BioTherapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Reversal New Lows Setup | Bearish Swing Setup | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Fell Below 20 DMA | Bearish | -2.54% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -4.96% | |
Inside Day | Range Contraction | -4.96% | |
Up 3 Days in a Row | Strength | -4.96% | |
Up 4 Days in a Row | Strength | -4.96% | |
20 DMA Resistance | Bearish | -4.17% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -4.17% |
Alert | Time |
---|---|
2x Volume Pace | about 17 hours ago |
1.5x Volume Pace | about 17 hours ago |
Down 5% | about 20 hours ago |
Fell Below Lower Bollinger Band | about 20 hours ago |
New 52 Week Low | about 20 hours ago |
Get a Trading Assistant
- Earnings date: 05/02/2024
Protalix BioTherapeutics, Inc. Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company's product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-105, a plant cell expressed pegylated recombinant acetylcholinesterase product candidate for biodefense and other indications; and an orally-administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant enzyme produced within carrot cells. Its product pipeline also comprises PRX-106 or pr-antiTNF, a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor and an antibody portion, which is being developed as a treatment of certain immune diseases, such as rheumatoid arthritis, Chrohn's disease, placque psoriasis, and other autoimmune disorders; and two additional undisclosed therapeutic proteins that are being evaluated in animal studies. It has a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. to develop and manufacture two proteins using its ProCellEx protein expression system. The company was founded in 1993 and is based in Carmiel, Israel.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Rheumatoid Arthritis Psoriasis Autoimmune Disorders Immune Disorders Pharmaceutical Industries Biodefense Choline Fusion Protein Enzyme Replacement Therapy Fabry Disease Teva Pharmaceutical Industries Cholinesterase Gaucher Disease Recombinant Dna Treatment Of Fabry Disease
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
SociableGnat503 9 months ago
TraderMike 9 months ago
SociableGnat503 9 months ago
So just trying to make sense of when to when to actually buy or stop buying given this.
View full discussion...
Indicator | Value |
---|---|
52 Week High | 3.55 |
52 Week Low | 1.09 |
Average Volume | 388,270 |
200-Day Moving Average | 1.57 |
50-Day Moving Average | 1.33 |
20-Day Moving Average | 1.20 |
10-Day Moving Average | 1.16 |
Average True Range | 0.07 |
RSI (14) | 39.76 |
ADX | 22.27 |
+DI | 15.26 |
-DI | 26.33 |
Chandelier Exit (Long, 3 ATRs) | 1.14 |
Chandelier Exit (Short, 3 ATRs) | 1.30 |
Upper Bollinger Bands | 1.31 |
Lower Bollinger Band | 1.10 |
Percent B (%b) | 0.26 |
BandWidth | 17.62 |
MACD Line | -0.04 |
MACD Signal Line | -0.05 |
MACD Histogram | 0.0073 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.35 | ||||
Resistance 3 (R3) | 1.35 | 1.28 | 1.31 | ||
Resistance 2 (R2) | 1.28 | 1.23 | 1.28 | 1.30 | |
Resistance 1 (R1) | 1.22 | 1.20 | 1.19 | 1.22 | 1.29 |
Pivot Point | 1.15 | 1.15 | 1.14 | 1.15 | 1.15 |
Support 1 (S1) | 1.09 | 1.10 | 1.06 | 1.09 | 1.01 |
Support 2 (S2) | 1.02 | 1.07 | 1.02 | 1.00 | |
Support 3 (S3) | 0.96 | 1.02 | 0.99 | ||
Support 4 (S4) | 0.96 |